A video game is FDA-cleared for children's ADHD. What its trial actually showed.

EndeavorRx is a video game the US Food and Drug Administration cleared in 2020 as a prescription treatment for ADHD in children — the player pilots a craft down a winding course, dodging and collecting targets, while the difficulty adapts to keep loading the player's attention [s2]. Its pivotal trial did improve a computer-based attention score, but by the FDA's own indication the game "may not display benefits in typical behavioral symptoms, such as hyperactivity," and is "not intended to be used as a stand-alone therapeutic device" [s2].

What it is, and what it was cleared to do

The FDA authorised EndeavorRx through the De Novo pathway on 15 June 2020, creating a new device type — a digital therapy device for ADHD, "a software intended to provide therapy for ADHD or any of its individual symptoms as an adjunct to clinician supervised treatment" (class II, 21 CFR 882.5803, product code QFT) [s2]. The cleared indication is narrow and unusually candid. It is "indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD" [s2]. The same document warns that patients "may not display benefits in typical behavioral symptoms, such as hyperactivity," and that the game "should be considered for use as part of a therapeutic program" alongside clinician-directed therapy, medication or educational support [s2].

The trial

The clearance rested largely on STARS-ADHD, a randomised controlled trial published in The Lancet Digital Health in 2020 [s1]. It enrolled 348 children aged 8-12, assigning 180 to the game (labelled AKL-T01) and 168 to a control app [s1]. The primary outcome was the change in the Test of Variables of Attention Attention Performance Index (TOVA API), a score from a computerised attention test. The game group improved by a mean of 0.93 (standard deviation 3.15) and the control group by 0.03 (SD 3.16); the between-group estimate of the median change was 0.88 (95% CI 0.24 to 1.49; p = 0.0060) [s1]. Adverse events were mild — frustration in 5 (3%) of 180 children and headache in 3 (2%) — with no serious adverse events, and children completed a mean of 83 of 100 expected sessions (SD 29.2) [s1]. The authors' own interpretation was carefully bounded: the intervention "might be used to improve objectively measured inattention" in paediatric ADHD [s1].

Why the endpoint is the story

The number that moved was a laboratory attention metric, not a rating of the child's behaviour at home or in class. That distinction is not a critic's gloss; it is written into the FDA's indication, which credits improvement "as measured by computer-based testing" while explicitly cautioning that benefits may not appear in "typical behavioral symptoms" [s2]. A 0.88 improvement on the TOVA API is statistically significant [s1], but whether it translates into a child who is less disruptive, better organised, or doing better at school is precisely what the trial's primary endpoint did not measure. For a treatment, that gap between a surrogate score and daily function is the whole question, and it remains open.

None of this makes the game harmful — the safety profile was benign [s1] — or useless as an adjunct. It makes the marketing claim ("clinically proven to treat ADHD") narrower than it sounds: proven, in one trial, to nudge a computerised attention test, in a specific slice of children, as one part of a broader programme [s1][s2].

What has changed since

The franchise has expanded faster than the independent outcome evidence. In 2024 the FDA cleared a second product, EndeavorOTC (510(k) K233496, 14 June 2024), moving the same adaptive-game approach into an over-the-counter product [s3]. That widens who can buy it without a prescription; it does not add a trial showing the approach improves the symptoms families actually seek help for.

What to watch

Whether independent trials — not funded or run by the maker — show a benefit on clinician- or parent-rated ADHD symptoms and real-world function, rather than on a computer attention score, and whether any head-to-head compares the game against the cheaper behavioural supports the FDA already lists as its intended companions [s2]. Until then, the strongest accurate claim is the FDA's own: an adjunct that improves a measured attention metric, not a substitute for the rest of ADHD care [s2].

Sources

• [s1] A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial — The Lancet Digital Health, 2020-04-01
• [s2] De Novo classification DEN200026: EndeavorRx (digital therapy device for ADHD) — U.S. Food and Drug Administration, 2020-06-15
• [s3] 510(k) K233496: EndeavorOTC — U.S. Food and Drug Administration, 2024-06-14

Related coverage: what "FDA-cleared" really means for prescription digital therapeutics, the modest effect sizes behind digital therapeutic approvals, and stimulant treatment for children with ADHD, and its evidence.